Yarrow Bioscience, Inc. (YARW) stock
YARWNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 11/30102% above fair value
$14.21+0.28 (+2.01%)
Close on Nov 17, 2026Market cap $37.94MP/E –Yield –
Yarrow Bioscience gross margin
Gross margin is gross profit as a percentage of revenue.
Yarrow Bioscience's gross margin for the twelve months ending Dec 31, 2021 was -259.6%. For fiscal 2021 it was -259.6%, against 93.4% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | -259.6% | −353.0 |
| FY2020 | Dec 31, 2020 | 93.4% | −6.6 |
| FY2019 | Dec 31, 2019 | 100.0% | +0.0 |
| FY2018 | Dec 31, 2018 | 100.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2021 | Dec 31, 2021 | -230.8% | +249.8 |
| Q3 FY2021 | Sep 30, 2021 | -688.7% | −777.4 |
| Q2 FY2021 | Jun 30, 2021 | -169.5% | −267.6 |
| Q1 FY2021 | Mar 31, 2021 | -161.3% | −245.8 |
| Q4 FY2020 | Dec 31, 2020 | -480.6% | −580.6 |
| Q3 FY2020 | Sep 30, 2020 | 88.7% | +5245.8 |
| Q2 FY2020 | Jun 30, 2020 | 98.2% | – |
| Q1 FY2020 | Mar 31, 2020 | 84.5% | – |
| Q4 FY2019 | Dec 31, 2019 | 100.0% | – |
| Q1 FY2019 | Mar 31, 2019 | -5157.1% | – |
See a number that looks wrong?